Literature DB >> 24719406

Murine coagulation factor VIII is synthesized in endothelial cells.

Lesley A Everett1, Audrey C A Cleuren2, Rami N Khoriaty3, David Ginsburg4.   

Abstract

The primary cellular source of factor VIII (FVIII) biosynthesis is controversial, with contradictory evidence supporting an endothelial or hepatocyte origin. LMAN1 is a cargo receptor in the early secretory pathway that is responsible for the efficient secretion of factor V (FV) and FVIII to the plasma. Lman1 mutations result in combined deficiency of FV and FVIII, with levels of both factors reduced to ~10% to 15% of normal in human patients. We generated Lman1 conditional knockout mice to characterize the FVIII secretion profiles of endothelial cells and hepatocytes. We demonstrate that endothelial cells are the primary biosynthetic source of murine FVIII and that hepatocytes make no significant contribution to the plasma FVIII pool. Utilizing RiboTag mice and polyribosome immunoprecipitation, we performed endothelial cell-specific messenger RNA isolation and quantitative polymerase chain reaction analyses to confirm that endothelial cells highly express F8 and to explore the heterogeneity of F8 expression in different vascular beds. We demonstrate that endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24719406      PMCID: PMC4055920          DOI: 10.1182/blood-2014-02-554501

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  A model for studying megakaryocyte development and biology.

Authors:  G J Murphy; A D Leavitt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII.

Authors:  W C Nichols; U Seligsohn; A Zivelin; V H Terry; C E Hertel; M A Wheatley; M J Moussalli; H P Hauri; N Ciavarella; R J Kaufman; D Ginsburg
Journal:  Cell       Date:  1998-04-03       Impact factor: 41.582

3.  Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.

Authors:  L Bi; A M Lawler; S E Antonarakis; K A High; J D Gearhart; H H Kazazian
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

4.  The structure and function of murine factor V and its inactivation by protein C.

Authors:  T L Yang; J Cui; A Rehumtulla; A Yang; M Moussalli; R J Kaufman; D Ginsburg
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

5.  Secretable human platelet-derived factor V originates from the plasma pool.

Authors:  R M Camire; E S Pollak; K Kaushansky; P B Tracy
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

6.  Outcome of orthotopic liver transplantation in patients with haemophilia.

Authors:  F H Gordon; P K Mistry; C A Sabin; C A Lee
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; M V Davies; R J Wise; D I Israel; A J Dorner
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

8.  Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo.

Authors:  K Yamamoto; V de Waard; C Fearns; D J Loskutoff
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

9.  Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow.

Authors:  P A Koni; S K Joshi; U A Temann; D Olson; L Burkly; R A Flavell
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

10.  Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment.

Authors:  W C Aird; J M Edelberg; H Weiler-Guettler; W W Simmons; T W Smith; R D Rosenberg
Journal:  J Cell Biol       Date:  1997-09-08       Impact factor: 10.539

View more
  70 in total

1.  Analysis of MCFD2- and LMAN1-deficient mice demonstrates distinct functions in vivo.

Authors:  Min Zhu; Chunlei Zheng; Wei Wei; Lesley Everett; David Ginsburg; Bin Zhang
Journal:  Blood Adv       Date:  2018-05-08

2.  Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.

Authors:  Alaknanda Mishra; Shailendra Arindkar; Preeti Sahay; Jerald Mahesh Kumar; Pramod K Upadhyay; Subeer S Majumdar; Perumal Nagarajan
Journal:  Int J Exp Pathol       Date:  2018-04-15       Impact factor: 1.925

3.  Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A.

Authors:  Melanie Rose; Kewa Gao; Elizabeth Cortez-Toledo; Emmanuel Agu; Alicia A Hyllen; Kelsey Conroy; Guangjin Pan; Jan A Nolta; Aijun Wang; Ping Zhou
Journal:  Stem Cells Transl Med       Date:  2020-03-12       Impact factor: 6.940

4.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

5.  The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A.

Authors:  Valder R Arruda
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

6.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

7.  Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.

Authors:  C K Baumgartner; J G Mattson; H Weiler; Q Shi; R R Montgomery
Journal:  J Thromb Haemost       Date:  2016-11-08       Impact factor: 5.824

Review 8.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

9.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

10.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.